BioRestorative Therapies Inc (BRTX)

[tjak]

News is out!
02/03/2008 http://traxxec.com/

Columbia River Resources Inc Focuses on RFID
Acquisition

(Pink Sheets OTC – CRVR.pk)



The Board of Columbia River Resources Inc. today announces significant reorganisation and resource targeting for its UK operations.


RFID specialists Traxxec Ltd, the latest acquisition, will become the sole focus of the Company’s operational activity. The new strategy was triggered by the creation of a new healthcare division within Rexam Plc, a key Traxxec partner, following their recent acquisition of Owens Illinois. Traxxec has a RFID solution for pharma packaging and has a signed 15 year agreement with Rexam, the world’s largest pharma bottle supplier.


On the 25th January 2008 Rexam Plc confirmed its intent to continue with the Traxxec licence agreement across the now newly combined European and US organisations, vastly increasing the available market opportunity.

The new focus coincides with the suspension of all activity and closing down of Medify Solutions Limited, the medical software solutions subsidiary. Despite several management attempts, the board no longer feel that resource-intensive Medify Solutions Limited warrants the high level of cost involved in delivering the Medify Remote and SystmOne Remote products to market. Columbia River Resources Inc will retain the IPR associated with the product, with a view to a possible sale in the future. The UK Limited Company will be wound up immediately.


In line with these changes there will be two significant corporate changes. Chief Executive Officer Christine Hill resigns effective 26th February 2008 and Mrs Amy Scopes is appointed CEO and Sole Officer in her place. Concurrent with these changes the Company will enacted a 1 for 250 reverse stock split, effective Tuesday 26th February.


Incoming CEO Amy Scopes comments “Despite several attempts to prove the success of Medify Solutions and its products, this has not been the case. We must therefore be critically realistic of the Company and the best use of its resources and funding. We feel that Traxxec Limited, with its product offering and licence agreement offers a far stronger, and more realistic, opportunity for our shareholders. In addition, in order to prepare the Company for the future it has been necessary to affect a significant stock split. Whilst we realise that this will not be popular, it is necessary for the future growth and stability of the Company.”


For more information please visit


www.Traxxec.com


NOTES:
1. Traxxec’s technology has worldwide patent protection


2. As part of the proposed business model and product development process the founders of Traxxec, funded by the pharmaceutical industry, have undertaken through two pilot installations a feasibility study on product design and as a consequence of this work, supplied a fully commercial product for evaluation purposes to a client with an annual buying capacity of 20,000,000 bottles. Traxxec Ltd was incorporated specifically to exploit this IP commercially. Since its incorporation, Traxxec Ltd has also supplied commercial product for a live, current phase III study in the US. As part of the technology transfer to Rexam Pharma, commercial product was successfully manufactured by them and supported by systems software provided by Traxxec Ltd. To date 21,000 units have been delivered.


3. The result of the comprehensive testing led to the decision by Rexam to enter into licensing negotiation and complete the 15 year licence agreement. The market sector for pharmaceutical product is in excess of 20 billion US dollars and bottles represent 30% of the available market per annum.


4. Traxxec has commercial arrangements with Assa Abloy identification Technologies, a Swiss based global leader in the supply of packaged RFID component parts and with Telsonic Ultrasonics for current and further product development work.


5. With the global patent and the relationship with Rexam, its first licence contract, the company is ideally positioned to deliver this potential within this very lucrative market, with revenues from both product sales and system integrations as well as revenues form any further development products in line with its business model.

For further information on Traxxec’s developments within the RFID/packaging industry please copy and paste the links below into your browswer.


http://www.in-pharmatechnologist.com/news/ng.asp?id=73668-rexam-traxxec-rfid-fda-pill-container

http://www.modplas.com/inc/mparticle.php?section=E-Weekly&thefilename=eweekly07012007_22

http://www.ceepackaging.com/2007/01/24/rfid-solution-for-containers/

http://rfid.idtechex.com/knowledgebase/en/sectionintro.asp?sectionid=115

http://www.packaging-gateway.com/features/feature1317/

http://www.rexam.com/files/pdf/fce_presskit.pdf


Ends


This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results to differ materially from those projected on the basis of such forward-looking statements. The words "estimate," "project," "intends," "expects," "believes," and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbour" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made and the Company undertakes no obligation to disclose any revision to these forward-looking statements to reflect events or circumstances after the date made or to reflect the occurrence of unanticipated events.